South Korea · Delayed Price · Currency is KRW Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 165.02 billion. The enterprise value is 163.36 billion.
| Market Cap | 165.02B |
| Enterprise Value | 163.36B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Meta Biomed has 26.62 million shares outstanding. The number of shares has increased by 19.78% in one year.
| Current Share Class | 26.62M |
| Shares Outstanding | 26.62M |
| Shares Change (YoY) | +19.78% |
| Shares Change (QoQ) | +5.20% |
| Owned by Insiders (%) | 21.89% |
| Owned by Institutions (%) | 6.91% |
| Float | 20.79M |
Valuation Ratios
The trailing PE ratio is 9.08 and the forward PE ratio is 7.42.
| PE Ratio | 9.08 |
| Forward PE | 7.42 |
| PS Ratio | 1.66 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | 16.34 |
| P/OCF Ratio | 8.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.79, with an EV/FCF ratio of 16.18.
| EV / Earnings | 9.29 |
| EV / Sales | 1.64 |
| EV / EBITDA | 5.79 |
| EV / EBIT | 7.09 |
| EV / FCF | 16.18 |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.49 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 4.59 |
| Interest Coverage | 5.85 |
Financial Efficiency
Return on equity (ROE) is 17.74% and return on invested capital (ROIC) is 9.21%.
| Return on Equity (ROE) | 17.74% |
| Return on Assets (ROA) | 7.97% |
| Return on Invested Capital (ROIC) | 9.21% |
| Return on Capital Employed (ROCE) | 18.87% |
| Revenue Per Employee | 330.17M |
| Profits Per Employee | 58.45M |
| Employee Count | 301 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.66 |
Taxes
In the past 12 months, Meta Biomed has paid 990.92 million in taxes.
| Income Tax | 990.92M |
| Effective Tax Rate | 5.38% |
Stock Price Statistics
The stock price has increased by +58.20% in the last 52 weeks. The beta is 0.62, so Meta Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +58.20% |
| 50-Day Moving Average | 5,662.60 |
| 200-Day Moving Average | 4,819.90 |
| Relative Strength Index (RSI) | 61.31 |
| Average Volume (20 Days) | 620,938 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 99.38 billion and earned 17.59 billion in profits. Earnings per share was 685.72.
| Revenue | 99.38B |
| Gross Profit | 53.09B |
| Operating Income | 22.10B |
| Pretax Income | 18.43B |
| Net Income | 17.59B |
| EBITDA | 27.26B |
| EBIT | 22.10B |
| Earnings Per Share (EPS) | 685.72 |
Balance Sheet
The company has 48.67 billion in cash and 46.32 billion in debt, giving a net cash position of 2.35 billion or 88.24 per share.
| Cash & Cash Equivalents | 48.67B |
| Total Debt | 46.32B |
| Net Cash | 2.35B |
| Net Cash Per Share | 88.24 |
| Equity (Book Value) | 113.96B |
| Book Value Per Share | 4,277.96 |
| Working Capital | 30.28B |
Cash Flow
In the last 12 months, operating cash flow was 20.42 billion and capital expenditures -10.32 billion, giving a free cash flow of 10.10 billion.
| Operating Cash Flow | 20.42B |
| Capital Expenditures | -10.32B |
| Free Cash Flow | 10.10B |
| FCF Per Share | 379.41 |
Margins
Gross margin is 53.42%, with operating and profit margins of 22.23% and 17.70%.
| Gross Margin | 53.42% |
| Operating Margin | 22.23% |
| Pretax Margin | 18.54% |
| Profit Margin | 17.70% |
| EBITDA Margin | 27.43% |
| EBIT Margin | 22.23% |
| FCF Margin | 10.16% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.47%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.47% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 4.37% |
| Buyback Yield | -19.78% |
| Shareholder Yield | -19.30% |
| Earnings Yield | 10.66% |
| FCF Yield | 6.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 23, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 2.51 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 7 |